Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.99
  • Today's Change-0.050 / -1.64%
  • Shares traded28.21k
  • 1 Year change+66.11%
  • Beta3.1023
Data delayed at least 15 minutes, as of May 17 2024 20:58 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 16-May-24
Select bar for recommendation details.
Recommendations16-May-24
Buy5
Outperform2
Hold2
Underperform0
Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Cellectis SA (ADR) have a median target of 6.50, with a high estimate of 11.00 and a low estimate of 3.00. The median estimate represents a 117.39% increase from the last price of 2.99.
High267.9%11.00
Med117.4%6.50
Low0.3%3.00

Earnings history & estimates in USD

On Apr 29, 2024, Cellectis SA (ADR) reported 4th quarter 2023 losses of -0.70 per share.
Average growth rate-30.01%
Cellectis SA (ADR) reported annual 2023 losses of -1.77 per share on Apr 29, 2024.
Average growth rate+4.98%
More ▼

Revenue history & estimates in USD

Cellectis SA (ADR) had 4th quarter 2023 revenues of 1.99m. This missed the 16.26m consensus estimate of the 7 analysts following the company. This was 48.07% below the prior year's 4th quarter results.
Average growth rate-30.01%
Cellectis SA (ADR) had revenues for the full year 2023 of 9.19m. This was 64.26% below the prior year's results.
Average growth rate+28.52%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.